TP53 and cancer: Certain HLA alleles are associated with the mutational landscape in cancer [24], but among coding mutations associated with progression (mutations in AR, TP53, ZMYM3, RB1, APC, ERF, CDK12, ZFP36L2) [25], none were more common in primary tumors of HLA‐A*02:01 carriers (Fig. 3A).